Progressive Familial Intrahepatic Cholestasis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Progressive Familial Intrahepatic Cholestasis – Drugs In Development, 2024 report and make more profitable business decisions.
Progressive familial intrahepatic cholestasis (PFIC) are a group of conditions in which liver cells do not release a digestive fluid, called bile, properly. This leads to a build-up of bile inside the liver cell, known as cholestasis. Cholestasis can damage the liver. The liver cells can start to die and become replaced with scar tissue. This leads to cirrhosis (severe scarring of the liver) which can cause a number of different problems
The Progressive Familial Intrahepatic Cholestasis drugs in development market research report provide comprehensive information on the therapeutics under development for Progressive Familial Intrahepatic Cholestasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Progressive Familial Intrahepatic Cholestasis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Progressive Familial Intrahepatic Cholestasis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 8 molecules, with 7 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Progressive Familial Intrahepatic Cholestasis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Progressive Familial Intrahepatic Cholestasis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Progressive Familial Intrahepatic Cholestasis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
CANbridge Life Sciences LtdHarvard Medical School
Ipsen SA
Jadeite Medicines Inc
Mirum Pharmaceuticals Inc
Qing Bile Therapeutics Inc
Shanghai Ark Biopharmaceutical Co Ltd
Takeda Pharmaceutical Co Ltd
Vivet Therapeutics SAS
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Progressive Familial Intrahepatic Cholestasis reports